Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (6081)	1/8/1999 11:48:00 AM
From: Linda Kaplan	Respond to of 7041

Good idea. Thanks. --Linda

To: Bill Wexler who wrote (6081)	1/8/1999 12:45:00 PM
From: Alan Newman	Read Replies (1) \| Respond to of 7041

How do you hedge your short position with options? Alan

To: Bill Wexler who wrote (6081)	1/8/1999 7:17:00 PM
From: allen menglin chen	Respond to of 7041

News that made ZONA jumped Extract Text of NY Times article Chat mentions as it refers to Zonagen. messages.yahoo.com@m2.yahoo.com ___________ (Interesting that none of the wires have yet to pick up on these articles. S-P & Zona are obviously keeping a low profile during the quiet period as the FDA reviews the application. (FDA frowns on PR at this time.) Note that in the NZ and BBC articles, S-Ps Director of Research gives an interview. To my knowledge, It's the first time conservative S-P, safely outside FDAs jurisdiction, boldly speaks up in defense against Viagra's negative remarks. Hype? or has S-P become confident based on continuing promising results.) __________________ "Schering-Plough Corp. and Zonagen, a tiny Texas biotechnology company, are expected to begin marketing Vasomax, a competitor to Pfizer's Viagra. Unlike Viagra, which analysts predict will have $1 billion in sales during its first year on the market, Vasomax is not expected to surpass $500 million in annual sales during its first four years on the market. But it may usher in this year's crop of drugs to address everything from age spots to facial hair on women. "We're really just beginning this phase of lifestyle drugs," said Viren Mehta, a partner at Mehta Partners, a biopharmaceutical investment research company in New York."